NDAORALSUSPENSION
Approved
Jan 2011
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
6
Data completeness
4/8 — Partial
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Children's Allegra Allergy is an oral suspension formulation of fexofenadine hydrochloride, a second-generation histamine H1-receptor antagonist indicated for allergic rhinitis and urticaria in pediatric patients. It provides non-sedating symptom relief by blocking histamine-mediated allergic responses in children.
LOE Approaching3.9 years to LOE
Product is in peak-to-decline transition with 3.9 years until loss of exclusivity, signaling need for lifecycle management and generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
Started Jun 2025
203 enrolled
Rhinitis Allergic
Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition
Started Feb 2011
80 enrolled
Healthy
Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions
Started Apr 2002
30 enrolled
Healthy
Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Started Apr 2002
44 enrolled
Healthy
Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Started Mar 2002
60 enrolled
Healthy
Worked on CHILDREN'S ALLEGRA ALLERGY at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.